25
3
9
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T3257 | UNC0638 | Influenza Virus , Histone Methyltransferase , Autophagy | |
UNC0638 is an inhibitor of β-protein lysine methyltransferases G9a(IC50<15 nM) and GLP(IC50=19 nM) with excellent potency and selectivity over a wide range of epigenetic and non-epigenetic targets. | |||
T7900 | BAY-474 | c-Met/HGFR | |
BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe | |||
T13748 | L-2-Hydroxyglutaric acid disodium | (S)-2-Hydroxyglutaric acid disodium | Histone Demethylase , Mitochondrial Metabolism |
L-2-Hydroxyglutaric acid disodium ((S)-2-Hydroxyglutaric acid disodium) is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activ... | |||
T1816 | (Z)-JIB-04 | NSC 693627,Z-JIB-04 | Others |
(Z)-JIB-04 (NSC 693627) is an isomer of JIB-04. | |||
T0499 | Oxybenzone | KAHSCREEN BZ-3,Benzophenone 3,Eusolex 4360,Escalol 567 | Apoptosis , Retinoid Receptor , Autophagy |
Oxybenzone (Eusolex 4360) is an organic compound used in sunscreens. It is a derivative of benzophenone. | |||
T39252 | TAK-418 | Histone Demethylase | |
TAK-418 is a selective and orally active inhibitor of LSD1/KDM1A enzyme with an IC50 of 2.9 nM. TAK-418 unlocks abnormal epigenetic mechanisms and improves autism symptoms in models of neurodevelopmental disorders. | |||
T5198 | Bobcat339 | Bobcat339 hydrochloride | DNA Methyltransferase |
Bobcat339 is a novel cytosine-based TET enzyme inhibitor (IC50s: 33/73 uM for TET1/2), but not DNMT3a, does not inhibit the DNA methyltransferase DNMT3a. | |||
T6793 | BRD7552 | Others | |
BRD7552 is an inducer of transcription factor PDX1, which increases insulin expression. BRD7552 increases PDX1 expression in mouse αTC cells but not βTC cells. | |||
T7400 | RRX-001 | Apoptosis , Dehydrogenase , Parasite | |
RRx-001 is a potent inhibitor ofglucose 6-phosphate dehydrogenase(G6PD) and with potent antimalarial activity | |||
T35363 | HM-cytosine | 5hmC,5-Hydroxymethylcytosine | Others |
HM-cytosine (5hmC) is a naturally occurring component of mammalian genomic DNA and is thought to be the sixth base of DNA [1]. HM-cytosine is an intermediate metabolite for demethylation of active DNA [2]. HM-cytosine is... | |||
T27423 | GNE-375 | GNE375,GNE 375 | Epigenetic Reader Domain , Carboxypeptidase , CDK |
GNE-375 is a selective and potent BRD9 inhibitor (IC50: 5 nM).GNE-375 inhibits BRD4, TAF1, and CECR2, and can be used to study epigenetic resistance. | |||
T4393 | MS049 2HCl (1502816-23-0(free base)) | Histone Methyltransferase | |
MS049 is a potent and selective inhibitor of PRMT4 (IC50 = 34 nM) and PRMT6 (IC50 = 43 nM). It is less active against additional type I PRMTs (IC50s = >130, >220, and 1.6 μM for PRMT1, PRMT3, and PRMT8, respectively) and... | |||
T15784 | LP99 | Epigenetic Reader Domain | |
LP99 is an epigenetic probe. LP99 disrupts the binding of BRD7 and BRD9 to chromatin in cells. LP99 is an effective and selective inhibitor of the BRD7 and BRD9 bromodomains (Kd: 99 nM against BRD9). | |||
T82458 | Epigenetic factor-IN-1 | Sirtuin | |
Epigenetic factor-IN-1 (40569Z) is an epigenetic factor inhibitor that exhibits potent binding affinity for SIRT7. It is utilized in the study of liver cancer [1]. | |||
T63103 | PRMT5-IN-17 | ||
PRMT5-IN-17 (Compound 6) is a PRMT5 inhibitor that exhibits antitumour activity. PRMT5, a protein arginine methyltransferase, is a novel anti-tumour target associated with epigenetic modifications. | |||
T76132 | β-N-Acetylhexosaminidase | ||
β-N-Acetylhexosaminidase is an exoglycosidase that catalyzes the hydrolysis of terminal non-reducing β-N-acetylgalactosamine and glucosamine residues in oligosaccharides for epigenetic applications [1] . | |||
T79131 | KAT modulator-1 | Histone Acetyltransferase | |
KAT modulator-1 (Compound 3), an epigenetics research tool, selectively interacts with the full-length p300 protein but not its catalytic domain [1]. | |||
T63138 | PRMT5-IN-16 | ||
PRMT5-IN-16 (Compound 20) is a PRMT5 inhibitor with antitumour effects. PRMT5, a protein arginine methyltransferase, is a novel anti-tumour target associated with epigenetic modifications. | |||
T76413 | PRMT5-IN-22 | ||
PRMT5-IN-22 (compound 53), an inhibitor of protein arginine methyltransferase 5 (PRMT5), exhibits anti-tumor activity. As a protein arginine methyltransferase, PRMT5 represents a novel anti-tumor target associated with e... | |||
T76414 | PRMT5-IN-23 | ||
PRMT5-IN-23 (compound 50), an inhibitor of protein arginine methyltransferase 5 (PRMT5), exhibits anti-tumor activity. As a novel anti-tumor target associated with epigenetic modification, PRMT5 belongs to the protein ar... | |||
T61012 | Bobcat339 hydrochloride | ||
Bobcat339 hydrochloride can be used in the field of epigenetics and as a starting point for new therapeutics targeting DNA methylation and gene transcription. Bobcat339 hydrochloride is a potent and selective cytosine-ba... | |||
T80212 | Lunasin | Parasite | |
Lunasin, a bioactive peptide derived from soybean, exhibits antioxidant, anti-inflammatory, anticancer, and anti-aging properties. It operates through an epigenetic mechanism linked to histone acetylation and has the abi... | |||
T9634 | Bomedemstat | ||
Bomedemstat (IMG-7289) is an orally active and irreversible inhibitor of the epigenetically active lysine-specific demethylase 1 (LSD1) in mouse models of myeloproliferative neoplasms (MPNs). Bomedemstat shows antineopla... | |||
T81932 | LIN28-IN-1 | ||
LIN28-IN-1 (compound 5) is a selective inhibitor targeting the RNA-binding protein LIN28, specifically binding to its cold shock domain (CSD). This compound robustly interrupts the LIN28-let-7 miRNA interaction with an I... | |||
T79801 | TCIP 1 | Epigenetic Reader Domain | |
TCIP 1 is a small molecule in the category of transcriptional/epigenetic covalent inhibitor probes (TCIPs) that forms covalent bonds with molecules targeting BCL6 and BRD4. This compound facilitates cell death gene expre... |
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T4832 | Cytosine | 6-Aminopyrimidin-2(1H)-one,4-Amino-2-hydroxypyrimidine,Cytosinimine | Endogenous Metabolite |
Cytosine (6-Aminopyrimidin-2(1H)-one) is a pyrimidine base that is a fundamental unit of nucleic acids. The deamination of cytosine alone is apparent and the nucleotide of cytosine is the prime mutagenic nucleotide in le... | |||
T5270 | 5-Methylcytosine | Others , DNA/RNA Synthesis , Endogenous Metabolite | |
5-Methylcytosine is a methylated nucleotide base found in eukaryotic DNA. In animals, the DNA methylation of cytosine to form 5-methylcytosine is found primarily in the palindromic sequence CpG. In plants, the methylated... | |||
T5255 | 5-Hydroxymethyluracil | 5-(Hydroxymethyl)uracil,Hydroxymethyl Uracil,a-Hydroxythymine | Others , Endogenous Metabolite |
5-Hydroxymethyluracil (a-Hydroxythymine) is an oxidation damage product derived from thymine or 5-methylcytosine. 5-Hydroxymethyluracil is a product of thymine dioxygenase. Additional deamination products such as 5-hydro... |
Cat No. | Product Name | ||
---|---|---|---|
L1200 | Epigenetics Compound Library | 960 compounds | |
Well-chosen 960 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs; | |||
L3510 | Methylation Compound Library | 131 compounds | |
131 methylation-related compounds that can be used for high-throughput and high-content screening. | |||
L2150 | Anti-Cancer Drug Library | 3159 compounds | |
A unique collection of 3159 anticancer drugs for high throughput screening (HTS) and high content screening (HCS); | |||
L3500 | Histone Modification Compound Library | 480 compounds | |
A unique collection of 480 histone modification related compounds for high throughput screening (HTS) and high content screening (HCS); | |||
L2160 | Anti-Cancer Active Compound Library | 3250 compounds | |
A unique collection of 3250 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS); | |||
L2120 | Anti-Cancer Clinical Compound Library | 2614 compounds | |
A unique collection of 2614 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS); | |||
L2100 | Anti-Cancer Compound Library | 7360 compounds | |
A unique collection of 7360 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS); | |||
L2110 | Anti-Cancer Approved Drug Library | 1825 compounds | |
A unique collection of 1825 approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS); | |||
L8200 | Anti-Aging Compound Library | 3324 compounds | |
A unique collection of 3324 anti-aging compounds for high throughput screening (HTS) and high content screening (HCS); |